CMND gets Yale IRB approval for CMND-100 Phase I/II Parts B and C recruitment
Clearmind Medicine received Yale IRB approval, enabling patient recruitment for Parts B and C of its CMND-100 Phase I/II trial following positive safety results.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.